Lyell Immunopharma, Inc.

Ownership Transactions Reported by 19 Insiders

Symbol
LYEL on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 Haskins Way, South San Francisco, CA

There are no Buy or Sell transactions made by insiders since 12/22/2023

Lyell Immunopharma, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
ARCH Venture Partners IX, LLC 10%+ Owner $83M Jun 21, 2021
Robert Nelsen Director, 10%+ Owner $83M Jun 14, 2024
GSK plc 10%+ Owner $69M Jun 21, 2021
Hans Edgar Bishop Director $10.7M Jun 14, 2024
Richard Klausner Director $8.33M Jun 14, 2024
Cathy Friedman Director $767K Jun 14, 2024
Lynn Seely President and CEO, Director $456K Feb 9, 2024
Gary K. Lee Chief Scientific Officer $120K Feb 9, 2024
Matthew Lang Chief Business Officer $114K Feb 9, 2024
Stephen J. Hill Chief Operating Officer $112K Feb 9, 2024
Charles W. Newton Chief Financial Officer $111K Feb 9, 2024
Tina M. Albertson Chief Medical Officer $9.23K Feb 24, 2023
Rahsaan Thompson Chief Legal Officer Feb 24, 2023
Heather D. Turner Chief General Counsel Mar 16, 2022
Elizabeth G. Nabel Director Jun 14, 2024
Otis W. Brawley Director Jun 14, 2024
William Jl Rieflin Director Jun 14, 2024
Elizabeth Homans Chief Executive Officer, Director Mar 16, 2022
Sumant Ramachandra Director Oct 31, 2024

Recent Insider Transactions by Companies or Individuals for Lyell Immunopharma, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.